Absci Corp (ABSI)
4.62
-0.12
(-2.53%)
USD |
NASDAQ |
May 17, 16:00
4.62
0.00 (0.00%)
Pre-Market: 20:00
Absci Research and Development Expense (Quarterly): 12.24M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.24M |
| December 31, 2023 | 12.27M |
| September 30, 2023 | 11.03M |
| June 30, 2023 | 12.11M |
| March 31, 2023 | 12.66M |
| December 31, 2022 | 11.32M |
| September 30, 2022 | 15.52M |
| June 30, 2022 | 16.24M |
| March 31, 2022 | 15.83M |
| Date | Value |
|---|---|
| December 31, 2021 | 15.77M |
| September 30, 2021 | 10.73M |
| June 30, 2021 | 11.04M |
| March 31, 2021 | 7.05M |
| December 31, 2020 | 4.597M |
| September 30, 2020 | 2.692M |
| June 30, 2020 | 2.252M |
| March 31, 2020 | 1.907M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.907M
Minimum
Mar 2020
16.24M
Maximum
Jun 2022
10.31M
Average
11.32M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.523B |
| Recursion Pharmaceuticals Inc | 67.56M |
| Creative Medical Technology Holdings Inc | 0.4224M |
| CytomX Therapeutics Inc | 22.05M |
| HOOKIPA Pharma Inc | 20.17M |